Literature DB >> 11407954

Status epilepticus arising de novo in hospitalized patients: an analysis of 41 patients.

N Delanty1, J A French, D R Labar, T A Pedley, A J Rowan.   

Abstract

Most of the information on predisposing factors and mortality in status epilepticus (SE) arises from data obtained from patients presenting to the casualty department. However, another population which is frequently seen by consultative neurologists are medically ill patients who develop SE while in hospital. These patients are often notoriously difficult to treat once SE arises. We sought to characterize patients at risk for SE arising when they are hospitalized for other reasons. By doing this, risk factors for developing SE and prognostic indicators might be determined. We retrospectively reviewed records from three urban hospitals in the United States to identify hospitalized patients developing SE over a 1 year period. SE was defined as a clinical seizure lasting 30 minutes or longer, or repeated seizures without recovery. Patients who were admitted in SE or for an epilepsy-related problem, or who were less than 1 year old were excluded from the study. Forty-one patients with in-hospital SE were identified. There were 28 males and 13 females with an age range from 1 to 91 years (mean: 60 years, median: 65 years). The mean interval from hospital admission to the onset of status epilepticus was 26 days. Nineteen (46%) patients had a prior history of either epilepsy or symptomatic seizures, and of these, 10 were inadequately treated as judged by serum anticonvulsant levels at the time SE developed. Focal brain abnormality was present in 26 (63%) patients, the most common of which was stroke (17 patients ). Major metabolic derangements including hypoxia, electrolyte imbalance, hepatic encephalopathy, and sepsis were present in 23 (56%) patients. Eleven (27%) patients were being treated with theophylline preparations at the time SE developed. Mortality in this group of patients with in-hospital SE was 61% (25 deaths), with about one-third dying while in status, and two-thirds dying subsequently in hospital. In this retrospective study, there was no clear relationship between mortality and the duration of SE in this group of patients. In-hospital development of SE is usually related to underlying focal brain abnormality, especially stroke, in combination with systemic metabolic derangement. Prognosis is poor, and appears to be more related to underlying conditions rather than to status duration. More accurate prospective studies are warranted. Copyright 2001 BEA Trading Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11407954     DOI: 10.1053/seiz.2000.0482

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  17 in total

1.  Mortality Associated with Status Epilepticus.

Authors:  Jane G. Boggs
Journal:  Epilepsy Curr       Date:  2004-01       Impact factor: 7.500

Review 2.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

3.  Complex detection, complex decisions: more detail on subclinical seizures in the acutely sick brain.

Authors:  Norman Delanty
Journal:  Epilepsy Curr       Date:  2014-05       Impact factor: 7.500

4.  Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.

Authors:  Annalena Hottinger; Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

5.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

Review 6.  Generalised convulsive status epilepticus: an overview.

Authors:  R Nandhagopal
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

7.  Impact of treatment on the short-term prognosis of status epilepticus in two population-based cohorts.

Authors:  Luca Vignatelli; Rita Rinaldi; Elisa Baldin; Paolo Tinuper; Roberto Michelucci; Massimo Galeotti; Piero de Carolis; Roberto D'Alessandro
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

8.  Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus.

Authors:  Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

Review 9.  Comorbidity in cirrhosis.

Authors:  Peter Jepsen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Outcome predictors for status epilepticus--what really counts.

Authors:  Raoul Sutter; Peter W Kaplan; Stephan Rüegg
Journal:  Nat Rev Neurol       Date:  2013-08-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.